Home › Islet Cell Adenoma › Washington
Islet Cell Adenoma clinical trials in Washington, DC
4 studies for Islet Cell Adenoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- Georgetown University, Washington D.C.
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
RecruitingPhase 3
- Investigative Site, Bethesda · 7 mi away
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
- National Institutes of Health ( Site 0125), Bethesda · 7 mi away
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
RecruitingPhase 2
- George Washington University Medical Center, Washington D.C.
Islet Cell Adenoma trials in other cities
- Rochester, MN5 studies
- Los Angeles, CA5 studies
- Phoenix, AZ4 studies
- St. Louis, MO4 studies
- Portland, OR4 studies
- Chicago, IL4 studies
- Philadelphia, PA3 studies
- Columbus, OH3 studies
- Boston, MA3 studies
- Jacksonville, FL3 studies
- Nashville, TN3 studies
- Lexington, KY3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.